AstraZeneca Cancer Drug Is First in Class, But FDA Nod Is Narrower Than Expected

MedCity News November 17, 2023
Frank Vinluan

The FDA approved AstraZeneca’s Truqap as a new treatment for advanced cases of breast cancer. The drug is the first in a new class of therapies addressing AKT genetic alterations.

The most common type of breast cancer now has a new targeted treatment: an AstraZeneca drug that’s first in a new class of therapies addressing a certain genetic signature. But the new approval is narrower than expected, which limits the total addressable market for the therapy.

The FDA approved the new drug, capivastertib, for use in combination with fulvestrant, an older AstraZeneca breast cancer therapy. The new drug will be marketed under the brand name Truqap.

Approval of Truqap covers the treatment of adults with advanced cases of breast cancer...

Today's Sponsors

Today's Sponsor